Abstract:

Hypertrophic Cardiomyopathy (HCM) is the common monogenic form familial pathological cardiac hypertrophy. HCM is an important cause of sudden cardiac death in the young adult and a major cause of morbidity in the elderly. We discuss here the molecular genetics and recent advances in the molecular genetics of HCM. HCM became the first cardiac disease for which a molecular genetic mechanism was identified. More than 100 mutations in nine genes, that encoding sarcomeric proteins have been identified in patients with HCM, which had led to the belief that HCM is a disease of contractile sarcomeric proteins of the cardiac muscle. Approximately two-thirds of all HCM cases are caused by the mutation of the myosin heavy chain (MyHC), cardiac troponin T (cTnT) and myosin binding protein-C (MyBP-C). Genotype-phenotype correlation studies suggest that mutations in the MyHC gene are associated with more extensive hypertrophy and a higher risk of SCD as compared to mutations in genes coding for other sarcomeric proteins, such as MyBP-C and cTnT. However, there is a noteworthy variability and factors, such as modifier genes and probably the environmental factors affect the phenotypic expression of HCM. The results of different functional studies suggest that in spite of the variety of the mutations, the initial defects in HCM is abnormal cardiac myocyte function. In this era of genetics and upcoming future of precision medicine, good knowledge of its molecular basis of any disease is crucial for patient management, and HCM is not different.

Key words: Cardiomyopathy, Genetics, Pathogenesis, Mutation.

Introduction:

Sixty years ago Dr. Robert Donals Teare, a pathologist of St. George Hospital in London first accounted for hypertrophic cardiomyopathy (HCM). HCM is primarily a cardiac disease that is one of the most common forms of heritable cardiac diseases. HCM is the most common monogenetic disorder with a prevalence of 0.2% irrespective of gender, race or ethnicity. HCM results in thickening of the myocardial wall and is almost always inherited as an autosomal dominant trait caused by point mutations in structural proteins within the contractile apparatus of cardiac myocytes. In HCM myocardial changes are characterized by the presence of excessive ventricular hypertrophy in the absence of conditions causing physiologic hypertrophy such as hypertension, valvular aortic stenosis, or the athletic heart. HCM patients may remain asymptomatic for a very long time but may also present with varieties of clinical presentations like dyspnea, angina, palpitation, syncope and sometimes sudden cardiac death (SCD) may be the first presenting symptom. It is a prominent cause of sudden cardiac death in young adults.

Genetics of HCM:

HCM became the first cardiac disease for which a molecular genetic mechanism was identified. It has been noted that 55 to 70% of the HCM is caused as a consequence of genetic mutations. The most common genetic mutation has been identified as responsible for HCM are found within thirteen genes. Mutations have been identified in patients with HCM in ten genes that encode for contractile sarcomeric proteins, two genes that code for non-sarcomeric proteins and one in the mitochondrial genome.
The discovery of a missense mutation in the MYH7 gene, which encodes the β-myosin heavy chain, about two decades ago, provided the first evidence to the molecular genetic basis of HCM. HCM is a disease of the sarcomere and contractile elements of the myocardium. It is now recognized that HCM is a disease which is autosomal dominant in inheritance, caused by a mutation in the genes for sarcomeric proteins, resulting in myocyte disarray and hypertrophy, with or without fibrosis and small vessels abnormality. Subsequent discoveries of other sarcomeric protein abnormalities, like α-tropomyosin gene (TPM1), cardiac troponin T (TNNT2), troponin I, myosin binding protein C (MYBPC), essential myosin light chain, cardiac actin, titin, cardiac alpha-myosin, and troponin C, lead to the concept that HCM is disease of the sarcomere. It is proposed that the sarcomeric mutation reduces the myocardial contractility, which in turn leads to increased cellular stress. Stressed myocytes produce trophic and mitotic factors that ultimately cause the myocardial changes. It is seen that MYH7 and TNNT2 mutation reduces the contractility of the myocytes. TNNT2 gene mutation is thought to alter cross-bridge kinetic, thereby limiting the shortening velocity of the cardiac myocyte and increase the energetic cost of contraction. However, the TPM1 mutation may also show enhanced cardiac output and filamentous motility in the submaximal concentration of calcium ion. Both the active and passive phases of the diastole are abnormal in HCM.

**Genes and mutations associated with HCM:**

During the last three decades, genetic cause for many cardiovascular diseases has been identified and HCM is most important of them. More than 100 different mutations in the genes that code for sarcomeric contractile proteins have been identified in patients with HCM (Table I). HCM is often presented with triple-repeat syndromes for which several causal mutations have been identified. Collectively these data suggest that in HCM, hypertrophy of the myocardium in spite of not having increased external load can occur as a result of mutations in various genes. Though hypertrophy is a common response of the myocardium to all sorts of stress and injury, however, hypertrophy may occur due to mutations in the non-sarcomeric proteins coding genes that are often presented with other cardiac and non-cardiac phenotypes.

Dr. Seidman mapped the first responsible gene for HCM, MYH7 on chromosome 14q12. Subsequent screening of this gene led to the identification of the R403Q missense mutation, which is the most commonly described mutation in HCM. The MYH7 gene is comprised of 40 exons and codes for a 6 kb mRNA and a 220 kD protein. It is the predominant myosin isoform comprising >90% of the total myosin in the human ventricles. Mutations in the MYH7 gene are the most common cause of HCM and responsible for 35-50% of all HCM cases. More than 60 different mutations of this gene have been accounted, and most of them are missense mutations. Hotspot for mutation of MYH7 gene is located in the codons 403 and 71925-26. Two small (E930 and G10) and one large (exon 40 and 3′ untranslated region) deletion and one insertion/deletion (changing AA 395-404) mutations in the MYH7 gene have been described.

| Gene       | Symbol | Locus | Frequency | Mutations                          |
|------------|--------|-------|-----------|------------------------------------|
| β-Myosin heavy chain | MYH7   | 14q12 | ~30%      | 67; mostly missense, a few nonsenes, and 3 deletion |
| Myosin binding | MYBPC  | 11p11.2 | ~20%      | 29; 11 missense/nonsense, 10 splice, 8 deletion/insertion |
| Cardiac troponin T | TNNT2  | 1q32  | ~20%      | 14; 12 missense, 1 splice and 1 deletion |
| α-Tropomyosin | TPM1   | 15q22.1 | ~5%       | 4 missense mutations |
| Cardiac troponin I | TNNT3  | 19p13.2 | ~5%       | 7 missense and 1 deletion mutations |
| Myosin light chain | MYL3   | 3p21.3 | <5%       | 2 missense mutations |
| Myosin light chain | MYL2   | 12q23 | <5%       | 7 missense and 1 truncation mutations |
| α cardiac actin | ACTC   | 11q   | <5%       | 2 missense mutations |
| Titin       | TTN    | 2q24.1 | <5%       | 1 missense mutation |
| α-Myosin heavy chain | MYH6   | 14q   | Rare      | 1 missense and 1 rearrangement mutations |
| K voltage gated channel | KCNQ4  | 1p34  | Rare      | 1 deletion mutation in conjunction with deafness |
| Protein kinase A | PRKAG2 | 7q22  | Rare      | 1 point mutation in conjunction with WPW |
| Mitochondrial DNA | MTTI   | -     | Rare      | tRNA isoleucine and tRNA glycine |
The second most common gene responsible for human HCM is the myosin binding protein-C (MYBPC) gene, which is located on chromosome 11q13. MYBPC gene mutations are responsible for about 20% to 25% of all HCM cases. This gene is comprised of 35 exons that span approximately 23 kb of DNA on the chromosome. More than 29 different mutations of MYBPC comprised of missense, deletion, and splice junction mutations have been identified. These mutations commonly affect the splice junctions and the binding sites for MyHC and titin proteins.

The third most common gene responsible for HCM is the TNNT2 that code for the cardiac troponin T (TNNT2), which account for approximately 20% of all HCM cases. It is located on chromosome 1q3 and through alternative splicing, encodes several isoforms in the heart. More than 20 mutations in the TNNT2 gene have been identified and codon 92 is considered a hot spot for the mutation. The majority of the mutations in TNNT2 are missense and deletion mutations that involve the splice donor sites and lead to truncated proteins. Overall, mutations in the three most common genes responsible for HCM, namely the MYH7, MYBPC, and TNNT2, account for approximately three-fourths of all HCM cases.

Identification of mutations in the contractile sarcomeric proteins led to the conception that HCM is a disease of contractile sarcomeric proteins. Systematic screening of HCM cases for mutations in genes encoding for other sarcomeric proteins led to identification of mutations in a-tropomyosin (TPM1), cardiac troponin I (TNNT3), essential and regulatory light chains (MYL2 and MYL3), a cardiac actin (ACTC), and titin. Overall, the frequencies of these mutations are relatively low and each of the above genes accounts for <5% of all HCM cases.

In addition to mutations in contractile sarcomeric proteins, mutations in two genes encoding for non-sarcomeric proteins also have been identified in patients with HCM. Recently, a deletion mutation in a potassium voltage-gated channel, KCNQ4 located on chromosome 1p34, in a family with congenital deafness and HCM was described. More recently, a point mutation in the AMP-activated gamma 2 non-catalytic subunit of protein kinase A (PARAG2) located on chromosome 7q22-q23 was described in two families with HCM and Wolff-Parkinson-White syndrome. Furthermore, mutations in mitochondrial genes encoding for tRNA isoleucine and tRNA glycine also have been associated with HCM. Thus, HCM is a genetic model of cardiac hypertrophy caused by a diverse array of mutations in a variety of genes, with the pure form (no other cardiac or noncardiac phenotype) resulting from mutations in contractile sarcomeric proteins.

**Molecular pathogenesis of HCM:**

It is evident from in vivo and in vitro studies that the mutations in the genes responsible for HCM lead to impaired contractile performance of the cardiac myocyte. The phenotype of sarcomeric disarray, hypertrophy and increased fibrosis are secondary to the primary defect of impaired contractile performance. To compensate for the contractile impairment, stress-responsive growth factors are released, which subsequently stimulate myocyte hypertrophy and fibroblast proliferation.

Approximately one-third of the myofibrillar proteins are the b-myosin protein, the motor unit of the sarcomere. It has a globular head that contains actin and ATP binding domains. Numerous myosin molecules assemble to form the sarcomeric thick filament. MYBPC is another thick filament that binds to myosin in the A band region of the sarcomere. It is also attached with the titin. Binding of MyBP-C to myosin and titin provides further stability to the structure of the sarcomere. Thin filaments, comprised of actin and troponin-tropomyosin complex, are involved in the generation force, as well as in the transmission of the force to cell boundaries. Cardiac troponin T, a-tropomyosin, and troponin I, each comprises <5% of the total myofibrillar protein. Troponin complex plays a major role in the Ca2+ regulation of cardiac contraction and relaxation.

Mutations in the sarcomeric genes cause structural changes that affect the sarcomere and myofibril formations. Several studies have revealed that the majority of the mutant sarcomeric proteins incorporate into myofibrils and sarcomeres. Incorporation of mutation affected sarcomeric proteins into sarcomere varies according to the mutation and is reduced for a truncated mutation in the MyBP-C. However, when these abnormal proteins are incorporated at high levels, they may induce sarcomere dysgenesis and myofibrillar disarray. The globular head region of b-MyHC contains a catalytic site for ATP hydrolysis that hydrolyzes ATP to ADP and inorganic phosphate. This function is markedly reduced as a consequence of mutations in MyHC and other sarcomeric proteins.

Repeated interaction of MyHC and actin is facilitated by binding and release of Ca2+. Mutations in sarcomere proteins could affect Ca2+ sensitivity and thus affect the interaction between actin and myosin filaments during the cardiac cycles. Though many studies show an enhanced Ca2+ sensitivity is imparted by the mutant of the sarcomeric proteins, the results remain controversial as they varied according to the experimental conditions. However the mutation-specific increase in Ca2+ sensitivity of contractile elements in cardiac myocytes could play a major role in
inducing cardiac specific phenotypes in HCM. Mutations in the b-MYHC impair the ability of the affected myosin protein to displace thin actin filaments. Mutations associated with a poor prognosis shows distinct effect than those associated with a benign prognosis. The mutant myosin shows impaired ability to displace actin filaments that reflects its reduced binding affinity for the actin filaments. Likewise, the interaction between the thin and thick filaments is also compromised in mutant MYH7.

Though the HCM is defined as the cardiac hypertrophy in the absence of increased external load, it is often a late manifestation of the disease and it is frequently absent in a significant number of patients having the causal mutation in the sarcomeric and non-sarcomeric genes that were mentioned earlier. Cardiac hypertrophy is the response of the myocardium to all forms of stress and injury. It is suggested that the hypertrophy in HCM is compensatory to the triggering stimulus usually provided by the abnormal contractile sarcomeric proteins produced as a consequence of mutations in the causal genes.

Conclusion:

HCM is a worldwide cardiovascular disease. From its first description by Teare to our current body of knowledge has rapidly advanced. Genetic variants, molecular mechanisms, and clinical phenotypes of HCM vary on a patient-by-patient basis. In summary, mutations in ten contractile sarcomeric genes, two non-sarcomeric genes, and mitochondrial DNA is associated with the pathogenesis of HCM. The results of different functional studies suggest that in spite of the variety of the mutations, the initial defects in HCM is abnormal cardiac myocyte function. In this era of genetics and upcoming future of precision medicine, good knowledge of its molecular basis of any disease is crucial for patient management, and HCM is not different. In this article, we shed some lights on the molecular genetic basis of the HCM.

References:

1. Houston BA, Stevens GR. Hypertrophic cardiomyopathy: a review. Clinical Medicine Insights Cardiology 2014;8(Suppl 1):53-65.
2. McKenna WJ, Sen-Chowdry S. From Teare to the present day: a fifty year odyssey in hypertrophic cardiomyopathy, a paradigm for the logic of the discovery process. Revista espanola de cardiologia 2008;61(12):1239-44.
3. Maron BJ. Hypertrophic cardiomyopathy. Current problems in cardiology 1993;18(11):639-704.
4. Watkins H, Rosenzweig A, Hwang D-S, Levi T, McKenna W, Seidman CE, et al. Characteristics and Prognostic Implications of Myosin Missense Mutations in Familial Hypertrophic Cardiomyopathy. New England Journal of Medicine 1992;326(17):1108-14.
5. Compton G, Nield L, Dragulescu A, Benson L, Grosse-Wortmann L. Echocardiography as a Screening Test for Myocardial Sarring in Children with Hypertrophic Cardiomyopathy. International journal of pediatrics 2016;16:6.
6. Jacoby DL, DePasquale EC, McKenna WJ. Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. Canadian Medical Association journal 2013;185(2):127-34.
7. Voiliot D, Huttin O, Hamaache N, Filippetti L, Vaugrenard T, Aliot E, et al. Impact of Global and Segmental Hypertrophy on Two-Dimensional Strain Derived from Three-Dimensional Echocardiography in Hypertrophic Cardiomyopathy: Comparison with Healthy Subjects. Journal of the American Society of Echocardiography 2015;28(9):1093-102.
8. King TC. Elsevier's Integrated Pathology. Boston: Mosby; 2007.
9. Ragosta M. Textbook of Clinical Hemodynamics. Virginia: Saunders/Elsevier; 2008.
10. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363(9424):1881-91.
11. Lind JM, Chiu C,SENSarian C. Genetic basis of hypertrophic cardiomyopathy. Expert review of cardiovascular therapy 2006;4(6):927-34.
12. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. European journal of clinical investigation 2010;40(4):560-69.
13. Pasquale F, Syrris P, Kasp I, Mogensen J, McKenna WJ, Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circulation: Cardiovascular Genetics 2012;5(1):10-17.
14. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92(4):785-89.
15. Baxi AJ, Restrepo CS, Vargas D, Marmol-Velez A, Ocearionez D, Murillo H. Hypertrophic cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. Radiographics: a review publication of the Radiological Society of North America, Inc. 2016;36(2):353-54.
16. Fujita E, Nakanishi T, Nishizawa T, Hagiwara N, Matsuoka R. Mutations in the cardiac troponin T gene show various prognoses in Japanese patients with hypertrophic cardiomyopathy. Heart and vessels 2013;28(6):785-94.
17. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. Journal of molecular and cellular cardiology 2001;33(4):655-70.
18. Krakor J, Viswanathan SK, Knoll R, Sadyayappan S. Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants. Frontiers in physiology 2016;7:499.
19. Marian AJ. Genetics for Cardiologists: The Molecular Genetic Basis of Cardiovascular Disorders. Limassol: Remedica; 2000.
20. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. The New England journal of medicine 1989;321(20):1372-78.
21. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62(5):999-1006.
22. Jaenicke T, Diederich KW, Haas W, Schleicher J, Lichter P, Pfordt M, et al. The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product. Genomics 1990;8(2):194-206.

23. Swyngedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiological reviews 1986;66(3):710-71.

24. Seidman CE, Seidman JG. Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic research in cardiology 1998;93Suppl 3:13-16.

25. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familiar hypertrophic cardiomyopathy. The Journal of clinical investigation 1994;93(1):280-85.

26. Dausse E, Komajda M, Fetter L, Dubourg O, Dufour C, Carrier L, et al. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. The Journal of clinical investigation 1993;92(6):2807-13.

27. Nakajima-Taniguchi C, Matsu H, Eguchi N, Nagata S, Kishimoto T, Yamauchi-Takihara K. A novel deletion mutation in the beta-myosin heavy chain gene found in Japanese patients with hypertrophic cardiomyopathy. Journal of molecular and cellular cardiology 1995;27(12):2607-12.

28. Marian AJ, Yu QT, Mares A, Hill R, Roberts R, Perryman MB. Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. The Journal of clinical investigation 1992;90(6):2156-65.

29. Cuda G, Perrotti N, Perticone F, Mattioli PL. A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy. Heart 1996;76(5):451-52.

30. Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circulation research 1997;80(3):427-34.

31. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. The New England journal of medicine 1998;338(18):1248-57.

32. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nature genetics 1995;11(4):438-40.

33. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. The New England journal of medicine 1995;332(16):1058-64.

34. Anderson PA, Greig A, Mark TM, Malouf NN, Oakeley AE, Ungerleider RM, et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circulation research 1995;76(4):681-86.

35. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77(5):701-12.
52. Marian AJ, Yu QT, Mann DL, Graham FL, Roberts R. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circulation research 1995;77(1):98-106.

53. Sweeney HL, Stracsko AJ, Leinwand LA, Tikunov BA, Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. The Journal of biological chemistry 1994;269(3):1603-5.

54. Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. The Journal of clinical investigation 1999;103(10):1459-67.

55. Morimoto S, Yanaga F, Minakami R, Ohtsuki I. Ca^2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. The American journal of physiology 1998;275(1 Pt 1):C200-07.

56. Cuda G, Fananapazir L, Epstein ND, Sellers JR. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. Journal of muscle research and cell motility 1997;18(3):275-83.

57. Fujita H, Sugiura S, Momomura S, Omata M, Sugi H, Sutoh K. Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. The Journal of clinical investigation 1997;99(5):1010-15.

58. Blanchard E, Seidman C, Seidman JG, LeWinter M, Maughan D. Altered cross bridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circulation research 1999;84(4):475-83.

59. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355(9197):58-60.